1-4 of 4
Authors: David Rial
Journal Article
Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis Open Access
Open Forum Infectious Diseases, Volume 10, Issue 11, November 2023, ofad526, https://doi.org/10.1093/ofid/ofad526
Published: 27 October 2023
Journal Article
Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance Open Access
Open Forum Infectious Diseases, Volume 9, Issue 11, November 2022, ofac610, https://doi.org/10.1093/ofid/ofac610
Published: 08 November 2022
Journal Article
Changes in Quality of Sleep, Mood, and Other Neuropsychiatric Symptoms After Switching Dolutegravir/Lamivudine/Abacavir to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Randomized Study of People With Human Immunodeficiency Virus With Poor Sleep Quality: GESIDA 10418 Open Access
Open Forum Infectious Diseases, Volume 9, Issue 9, September 2022, ofac345, https://doi.org/10.1093/ofid/ofac345
Published: 06 August 2022
Journal Article
Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV-2 Variants in Naïve and COVID-19-Convalescent Individuals Open Access
Open Forum Infectious Diseases, Volume 8, Issue 10, October 2021, ofab468, https://doi.org/10.1093/ofid/ofab468
Published: 24 September 2021
